Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ439439,5-0,68
KB0,00
PKN46,0146,061,53
Msft210,65210,691,64
Nokia3,353,47-1,40
IBM121,81121,860,71
Daimler AG46,3746,4050,76
PFE36,6636,671,35
30.09.2020 20:33:47
Indexy online
AD Index online
select
AD Index online
 

  • 30.09.2020 17:29:22
Thrombogenics NV (THR.BR, Brussels)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
2,46 -0,20 -0,01 15 696
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 30.09.2020
Popis společnosti
Obecné informace
Název společnostiOxurion NV
TickerOXUR
Kmenové akcie:Ordinary Shares
RICOXUR.BR
ISINBE0003846632
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky30.06.2020
Počet zaměstnanců k 31.12.2019 77
Akcie v oběhu k 30.06.2020 38 291 950
MěnaEUR
Kontaktní informace
UliceGaston Geenslaan 1
MěstoHEVERLEE
PSČ3001
ZeměBelgium
Kontatní osobaWouter Piepers
Funkce kontaktní osobyGlobal Head of Corporate Communications and Investor Relations
Telefon3 216 751 310
Fax3216751311
Kontatní telefon3 216 751 310

Business Summary: Oxurion NV, formerly known as ThromboGenics NV, is a Belgium-based biopharmaceutical company, which focuses on the development and commercialization of ophthalmic medicines. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The Company is active domestically, as well as operates through offices located in the United States and Ireland.
Financial Summary: BRIEF: For the six months ended 30 June 2020, Oxurion NV revenues decreased 30% to EUR1.3M. Net loss decreased 61% to EUR13.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Impairment losses decrease from EUR16.9M (expense) to EUR0K, Research and development expenses decrease of 25% to EUR9M (expense), Selling expenses decrease of 48% to EUR1.8M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biotechnology & Medical Research - NEC
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSPharmaceutical Preparation Manufacturing
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 30.09.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Member of the Executive Committee, Executive Director as Representative of ViBio BVBAPatrik De Haes-09.04.200905.02.2007
Chief Financial Officer, Member of the Executive CommitteeDominique Vanfleteren-08.01.201508.01.2015
Head of Human ResourcesJulie Binon-
Global Head of Clinical and Product Development, Member of the Executive CommitteeAndy De Deene-
Chief Commercial Officer, Member of the Executive CommitteeVinciane Vangeersdaele-08.11.201708.11.2017
Chief Medical OfficerGrace Chang-01.08.202001.08.2020
Chief Scientific Officer, Member of the Executive BoardJean Feyen-